Search Results

Displaying Results 1-3 of 3 "'AKBA'"

Jul 01, 2026, 08:39 ET Kollo Health Launches FLEX+ Advanced Joint Support Featuring AprèsFlex®

freedom to moveA key component of FLEX+ is AprèsFlex 5-Day Joint Support, a patented Boswellia serrata extract standardized to 20% AKBA (3-O-acetyl-11-keto-β-boswellic acid), the boswellic acid most closely associated with joint-support activity.Unlike conventional Boswellia extracts

More news about: PLT Health Solutions, Inc.


May 13, 2026, 08:41 ET Grow in Health Launches KumbreX® GROW FLEX Featuring AprèsFlex® 5-Day Joint Support

patented, synergistic Boswellia serrata gum resin extract. The oral bioavailability of the active component, acetyl-11-keto-beta-boswellic acid (AKBA), from AprèsFlex has been shown to be about 52% higher than other commercially available Boswellia extracts, allowing for a lower daily dose with improved

More news about: PLT Health Solutions


Dec 01, 2025, 07:00 ET Q32 Bio Sells Complement Inhibitor ADX-097

autoimmune and inflammatory diseases, today announced that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (NASDAQ: AKBA) ("Akebia")."This transaction strengthens our cash position through additional non-dilutive funding, extending our runway into the second half

More news about: Q32 Bio


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.